Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal ...